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New technology now supports direct online measurements
of total dialysis dose per treatment, Kt. An outcome-based,
nonlinear method for estimating target Kt in terms of ionic
clearance measurements and body surface area (BSA) has
been described recently. This is a validation study of the new
method that evaluates the relationship between the (actual
Kttarget Kt) difference and death risk. Patients with Kt
measurements during March 2004 were identified
(N¼ 59 644). Target Kt was determined for each patient using
the new method. Patients were then grouped by (actual
Kttarget Kt) decile. They were also grouped by (actual
URRtarget URR) decile. Cox analysis-based risk profiles were
constructed using those groupings. The (actual Kttarget Kt)
difference profiles suggested improving death risk as Kt
increased from below target to equal target. Risk ratios then
flattened and remained so until (actual Kttarget Kt) reached
the highest decile at which it appeared to improve,
suggesting a possible biphasic profile. The (URRtarget URR)
risk profile was U-shaped. Death risk was related to the
difference between the actual Kt and a target Kt value
selected using the new nonlinear method. The method is
therefore valid for prescribing and monitoring hemodialysis
treatment.
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We have described a new method for prescribing total
hemodialysis treatment (Kt: l/treatment) targets in terms of
body surface area (BSA: m2).1 Small molecule clearance (K:
ml/min) was measured using an established online ionic
clearance (OLC) method2 and multiplied by treatment time
(t: min/treatment) to yield total treatment exposure or dose,
Kt. Functional forms evaluating target Kt values in terms of
BSA based on analyses of patient survival time were then
tested to determine which fit best the empirical data.1
Several curvilinear forms fit the data well and all suggested
comparable treatment targets.1 The best-fit form, however, was
a simple algebraic expression that produces a curve proceeding
from the 0, 0 origin (i.e., target Kt¼ 0; BSA¼ 0) increasing
with BSA such that target Kt increases more rapidly at low
BSA than at high BSA. A table showing target Kt in terms of
BSA calculated using that best-fit form was appended to the
manuscript1 and is reproduced here also as an Appendix.
Validating new methods requires a different patient
sample than the one used to develop the method. The
purpose of this project, therefore, was to evaluate the
association of the difference between the OLC-measured Kt
actually delivered to patients and a target Kt value (actual
Kttarget Kt) selected by the new method1 using a different
patient sample. The target Kt is a nonlinear function of BSA,
not a linear function of body size as is, for example, a Kt/BSA
or a Kt divided by a urea volume of distribution (V), Kt/V.
Therefore, it was necessary to evaluate the method using an
actual Kt minus target Kt difference instead of a value of Kt
or Kt/BSA. We also performed similar analyses using a more
familiar measure of dialysis dose, the urea reduction ratio
(URR: %), to illustrate the process.
RESULTS
The patient population is described first. Risks profiles for
BSA, Kt and URR will be presented before describing the
(actual Kttarget Kt) and the (URRtarget URR) relation-
ships that are the primary focus of these validation analyses.
Finally, the risk profiles evolving from those preplanned
analyses suggested the possibility of follow-up analyses that
will be presented last.
Patient sample and measurements
The original patient sample used to develop the new method
included 32 763 patients treated 3 times weekly who had at
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least one online measurement of Kt during December 2002.1
The current sample includes 59 664 patients treated 3 times
weekly who had at least one online measurement of Kt during
March 2004. A sizable subset of the sample (57 198; 95.9%)
also had at least one URR measurement during the month.
Table 1 summarizes the attributes of the patient sample.
The mean and median Kt were about 51 l/treatment.
The mean and median (actual Kttarget Kt) were þ 0.3 l/
treatment and þ 0.5, respectively. About 5% of patients were
treated at actual Kt that was 14.7 l/treatment less than target
and 5% were treated at Kt values that were 14.4 l/treatment or
more than target.
The mean and median URR in the subsample of patients
with a URR measurement were 73.4 and 74.1%, respectively.
The 5th–95th percentile range was 61.3–82.9. The average
(URR75%) was about 1.6 percentage units lower than
target; the 5th to 95th percentile for (URR75%) was –13.7
percentage units to þ 7.9, respectively.
The median and modal numbers of Kt determinations
during March 2004 were 12 and 13 measurements,
respectively. Three-fourths of patients had 10 or more
determinations and 92% had 5 or more. Ninety-two percent
(92%) of patients with URR data, on the other hand, had
only one URR determination.
BSA, Kt, and URR risk profiles
The risk profiles for BSA are shown in Figure 1. There
appeared a progressive improvement of risk with increasing
BSA throughout the range of BSA evaluated here whether the
analysis was adjusted for case mix or not.
The risk profiles for Kt are shown in Figure 2. The
unadjusted analysis suggests an improvement of risk with
increasing Kt that tended to level and then improve.
Adjusting statistically for case mix and/or BSA similarly
suggested improvement of risk with increasing Kt followed by
leveling of risk. The adjustments for case mix, and
particularly BSA, tended to reduce but not eliminate the risk
gradient (i.e., the curve appears less steep) seen in these
relationships. The general form of the risk to Kt relationship
was similar no matter the statistical adjustments made to the
data as found also during earlier studies.3,4
Table 1 | Descriptive statistics
Percentile
Variable Mean or % s.d. 1st 5th 25th 50th 75th 95th 99th
Age (years) 61.0 15.0 25.0 34.0 51.0 62.0 73.0 83.0 89.0
Gender (% female) 46.8
Race
Black (%) 41.9
White (%) 48.3
Other (%) 9.8
Diabetes (% yes) 52.0
Post Wt (kg) 76.4 20.7 41.5 48.8 61.9 73.3 87.5 114.7 140.0
BSA (m2) 1.86 0.25 1.34 1.47 1.68 1.84 2.01 2.30 2.53
Kecn (ml/min) 233.2 35.6 139.0 169.5 211.5 236.5 257.0 286.0 309.5
t (min) 219.6 28.8 155 180 203 218 240 258 295
Kt (l/treatment) 51.0 10.3 28.2 34.7 43.9 50.7 57.7 68.1 77.2
Target Kt (l/treatment) 50.7 4.5 40.8 43.5 47.6 50.6 53.6 58.2 61.6
Kt – target (l/treatment) 0.3 8.9 21.7 14.7 5.3 0.5 6.1 14.4 21.5
URR (%) 73.4 6.9 51.9 61.3 70.0 74.1 77.8 82.9 87.1
URR – 75 (%) 1.61 6.94 23.11 13.71 5.00 0.93 2.78 7.93 12.10
BSA, body surface area; Kecn, ionic clearance measured by OLC; Kt, the Kecn t product; t, treatment length; URR, the urea reduction ratio; Wt, body weight.
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Figure 1 | Risk profiles for BSA showing the death hazard ratio
for the deciles of BSA compared to a reference decile (Ref).
Unadjusted (Unadj: ’) and case mix adjusted (CM Adj: &) analyses
are shown. The hazard ratios are compared to a common reference
decile (Ref) for each analysis and the probability that each ratio is
not different from its reference value is shown by a symbol near the
ratio: #Po0.01, Po0.05, and þPo0.10. No symbol means not
different (P40.10).
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Figure 3 presents similar constructs for the URR. The
unadjusted risk profile suggests a U-shape in which risk is
higher at the extremes of the URR distribution than at its
middle. Minimum risk appeared close to URR¼ 75%.
Adjustments for case mix and/or BSA altered the relation-
ships so that the risk gradient is steeper. Furthermore,
continuing risk improvement is now observed throughout
the range of URR. In other words, adjusting the URR risk
profile, particularly for BSA, altered it to resemble the
unadjusted risk profile for Kt again confirming earlier
studies4 that suggest high risk at high URR is at least
partially attributable to the predominance of low BSA
patients in high URR deciles. Although the unadjusted
profile suggests a URR target of about 75% (minimum risk),
the BSA adjusted profile suggests a target exceeding 81%, the
minimum value of the upper decile, because there is no clear
zone of minimum risk.
Risk and the treatment to target difference for Kt and URR
The Kt therapy target was calculated for each patient from
her/his BSA using the nonlinear method1 and subtracted
from the actual Kt that was administered to the patient. The
hazard ratios for the (actual Kttarget Kt) deciles are shown
in Figure 4 and are compared to the no difference decile that
incorporates ‘0’ (1.6 to þ 0.5 l/treatment).
There appeared a progressive increase of risk as actual
treatment became less than target, that is, when (actual
Kttarget Kt) became more negative. Risk appeared to
flatten as (actual Kttarget Kt) moved into the positive range
(i.e. actual KtXtarget Kt). Risk then appeared to remain
stable until the last decile of (actual Kttarget Kt), for which
the hazard ratio was lower than the 0-point reference value.
Thus, the risk curve may be biphasic showing improvements
both before and after a region of level risk.
Figure 5 presents a similar construct for (URRtarget
URR). The reference group was 0.93 to þ 0.51 percentage
units. Risk was minimum when URR was close to 75% and
tended to increase when URR was less than 75%. Risk also
tended to increase as URR exceeded 75%, however, suggest-
ing a U-shaped, or reversed J-shaped, profile. Supplementary
analyses using target URR of 70 and 65% also produced
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Figure 2 | Risk profiles for Kt. Four levels of statistical adjustment are
shown: unadjusted (Unadj: ’), case mix adjusted (CM Adj: &), case
mix and BSA adjusted (CM and BSA: n), and BSA adjusted (BSA: m).
The hazard ratios are compared to a common reference decile (Ref)
for each analysis and the probability that each ratio is not different
from its reference value is shown by a symbol near the ratio:
#Po0.01, Po0.05, and þPo0.10. No symbol means not different
(P40.10).
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Figure 3 | Risk profiles for the URR. Four levels of statistical
adjustment are shown: unadjusted (Unadj:’), case mix adjusted (CM
Adj: &), case mix and BSA adjusted (CM and BSA: n), and BSA
adjusted (BSA: m). The hazard ratios are compared to a common
reference decile (Ref) for each analysis and the probability that each
ratio is not different from its reference value is shown by a symbol
near the ratio: #Po0.01, Po0.05, and þPo0.10. No symbol means
not different (P40.10).
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Figure 4 | Risk profile for the difference between delivered Kt and
the target Kt (actual Kttarget Kt). Values in parentheses are
negative values for the difference indicating that the delivered Kt was
lower than the target Kt. Values not in parentheses are positive values
indicating that the delivered Kt was higher than the target Kt. The
hazard ratios were compared to a reference decile that incorporated
‘0’ indicating no difference between the delivered and target Kt. The
probability that the hazard ratios were not different from the
reference decile is shown above the bars; ‘NS’: not different (P40.05).
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U-shaped, or reversed J-shaped, profiles similar to those
shown in Figure 5 (data not shown).
Additional analyses
The (actual Kttarget Kt) risk profile (Figure 4) suggested a
flattening of death risk as the difference approached zero and
moved into the positive range. The apparent improvement of
risk in the highest decile of the distribution was surprising.
Similarly, the reversed J-shaped forms of (URRtarget URR)
suggested the possibility of additional analyses. Therefore,
possible differences of BSA among (actual Kttarget Kt) and
(URR75%) deciles were evaluated using an analysis of
variance. Figure 6 summarizes the results.
There were differences of mean BSA among the (actual
Kttarget Kt) deciles (Figure 6, left panel). The mean BSA of
patients in the highest decile ([actual Kttarget Kt]X11.3)
was significantly greater than all other deciles. BSA in the first
decile ([actual Kttarget Kt]o11.0), on the other hand, was
not different from BSA in either the eighth or ninth deciles.
Similarly, the second, fifth, and sixth deciles were not
different. The BSA versus (actual Kttarget Kt) relationship
appeared as a shallow J-shape but the range of mean values
was constrained between 1.81 m2 (third and fourth deciles)
and 1.95m2 (10th decile). The mean BSA in deciles 1 and 9
were 1.89 m2 so the range of mean BSA was 0.14 m2 across all
deciles but only 0.08 m2 if the 10th is not considered.
Mean BSA became progressively smaller as (URR75%)
became progressively greater (right panel of Figure 6) so that
larger patients tended toward URR values lower than URR
¼ 75% while smaller patients were treated at URR that
exceeding that value. The mean BSA in the first (URR75%)
decile was 2.03 m2; it was 1.65 in the 10th decile; the range of
BSA was therefore 0.38 m2 across the deciles. The mean BSA
in each (URR75%) decile was significantly different from
all other deciles. The relationship between (URRtarget
URR) and BSA was strongly inverse.
DISCUSSION
This project was intended primarily as a formal validation
exercise to evaluate a new nonlinear method for judging
dialysis dose in terms of BSA using OLC technology.1
Evaluating risk in terms of an actual minus target Kt
difference was necessary because the target Kt is a nonlinear
function of BSA and not a simple linear ratio like Kt/BSA or
Kt/V. A ratio of Kt/V is constant across all values of V because
Kt¼ 0þ 1.2 V if the target Kt/V is 1.2. The ratio of Kt/V
is not fixed, however, if the relationship is nonlinear as
illustrated by Eq. 1) (see Materials and Methods). Prior work
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(Lowrie et al.1, Figure 8 in that paper), for example, implies a
Kt/V of 1.67, 1.52, 1.39, 1.28, 1.18, 1.10, and 1.03 for urea
volumes equaling 20, 25, 30, 35, 40, 45, and 50 l, respectively.
That pattern, indicating falling Kt/V with increasing V, is
similar to the one observed in clinical practice because
clinicians generally use higher URR, and therefore Kt/V, for
small patients than large.5
Profiles evaluating the association of death risk with
(actual Kttarget Kt) suggested that negative values,
indicating actual Ktotarget Kt, were generally associated
with higher risk than if (actual Kttarget Kt) was close to ‘0’.
Risk flattened as (actual Kttarget Kt) increased into the
positive range but appeared to improve when (actual
Kttarget Kt) exceeded 11.3 l/treatment. Thus, the new
method1 leads to reasonable minimum target Kt values for
small molecule directed treatment. The possibility remains,
however, that increasing Kt to much higher levels might
provide additional benefits for patients.
Analyses of (URRtarget URR), similar to the analysis of
(actual Kttarget Kt), were also performed. Those risk
profiles suggested that negative values, indicating that actual
therapy was less than URR¼ 75%, were associated with
higher risk than if the value of (URR75%) was near ‘0’. Risk
then appeared to increase as the difference proceeded into the
positive range so that the risk profile appeared U-shaped
indicating that high URR was associated with greater risk.
The finding suggesting better survival in the highest decile
of (actual Kttarget Kt) deserves discussion. The new
method1 may underestimate true target Kt for some patients.
That is unlikely because the risk profile appeared biphasic,
improving both before and after a region of flat risk. By
alternative, there may be a real survival advantage associated
with treatment at very high Kt so that the risk profile may be
truly biphasic. The management of mortal risk attributable to
small molecule associated pathology, for example, may be
adequately managed when actual Kt equals or exceeds target.
However, treatment at much higher levels may be associated
with a survival advantage attributable to better management
of other chemical species. Additional research is needed to
explain, and refute, or confirm this interesting finding.
The U-shaped risk profiles for URR, and the actual minus
target URR difference, also deserves comment. High values of
URR could be ‘toxic’ to patients by removing essential
nutrients, for example. That explanation is unlikely because
comparable U-shaped risk profiles associated with URR have
been reported before6 and no toxicity-related explanation has
yet been forthcoming. Furthermore, statistical adjustment for
body size, whether described as V6 or other measures,3,4,7,8
extinguishes the U shape to the profiles. That would not be
likely if the U shape were due to direct toxicity. It is therefore
more likely a function of body size differences among the
deciles as confirmed by Figure 6, right panel.
U-shaped risk profiles are observed with the single pool
and equilibrated values of Kt/V as well as simple division
of Kt by BSA, Kt/BSA.8 The extinction of the U shapes
by statistical adjustment for body size has been reported
before.3,4,6,7 Adjusting a Kt/V statistically for V, or close
correlates of V like height and weight4 or BSA, reduces the
analysis to the evaluation of Kt because the risk associated
with Kt/V is evaluated at a statistically constant value of V.9
Risk differences associated with Kt/V evaluated at constant V
must logically be due to differences of Kt.
Some argue from such observations that Kt/V and URR,
dimensionless parameters evolving from urea pharmaco-
kinetic models, are not well suited to prediction of a clinical
outcome like survival.10 The equations underlying the
models treat V simply as a diluent for urea without other
biological or epidemiological properties.11 However, body
size, V, is strongly associated with death risk in dialysis
patients.3,12 Thus, an important premise on which the
urea models are based is incorrect. The ratio Kt/V divides
one measure positively associate with survival, Kt, by
another, V.10 A high Kt/V, or URR, can therefore indicate
either a high Kt, favorable to survival, or a low V, unfavorable
to survival.
There is no biological imperative requiring that Kt, or
physiological functions generally, be judged as simple ratios
of body size like Kt/BSA or Kt/V. Indeed, the universal scaling
law suggests that physiological functions increase with body
size as a power function13,14 that has nonlinear mathematical
properties very similar to the method used here.1
We first reported routine use of OLC-related methods on
15 570 patients treated during April 2002;8 that increased to
33 328 by December.1 These data show that the OLC-tested
population was 59 664 in March 2004 – an increase of more
than 280% in 2 years. Thus, OLC-related technology is
finding widespread and increasing clinical use.
This new method has several advantages for those clinics
able to measure OLC. First, OLC actually measures Kt but
not V or Kt/V.2,15 Second, dialysis dose can be measured with
each treatment as suggested by the observation that the
average number of Kt measurements in a month was 12
compared to a single URR measurement. Third, the urea
kinetic premise issue10 is avoided and one need not worry
about U-shaped risk profiles or which statistical adjustment
is favored for evaluating the profiles to judge appropriate
treatment targets.4 Fourth, the now accepted underprescrip-
tion of Kt for small patients using a fixed Kt/V ratio7,8 is
avoided because the Kt prescribed for small patients is
proportionally higher than it is for large patients. Fifth, the
urea V is ambiguous; it is said to be about 15% less than V
estimated by anthropometric methods in chronic dialysis
patients16 but more than anthropometric V in acute dialysis
patients.17,18 The best value of V for division into OLC-
measured Kt is uncertain. BSA, on the other hand, is a simple
fixed transformation of height and weight19 that is well
understood by most clinicians. Sixth, post-dialysis blood
sampling is not necessary thereby avoiding cost, needle stick
risk, and the staff efforts necessary to assure that the post-
dialysis blood sample is properly drawn.
Finally, the new method is easily implemented at no
incremental cost in clinics able to measure OLC. A target Kt
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is selected for the patient’s BSA from a table, like the
one shown in the Appendix, and divided by t to estimate a
target OLC-measured K. The blood and dialysate flow rates
necessary to estimate an initial K are then selected from
manufacturers’ specifications for the dialyzer and used to
initiate the first treatment. K is then adjusted using OLC
information by manipulating the flow rates to achieve the
target Kt. Cumulative Kt can be monitored during the course
of treatment and the length of treatment can be extended if
necessary to achieve the target. The actual Kt at treatment’s
end can be compared to the target Kt and the difference used
to plan the next treatment.
These comments should be qualified in several ways. First,
the data are retrospective. Trials in which the Kt is delivered
at prespecified levels above and below target may give
different insights. Similarly, other analyses exploring different
ranges of Kt, or different (actual Kttarget Kt) ranges, may
suggest other conclusions. Second, the technology used to
measure Kt in this study is available only through a single
supplier and these patients were treated in clinics owned and/
or operated by the same company. Other suppliers (e.g.,
Gambro, AB: Stockholm, Sweden and Lakewood, CO, USA)
offer machines incorporating OLC technology;15 however,
other technologies have been suggested to support that
capability.20 Third, possibilities for interest of conflicts exist
in this work. All these co-authors are employees of, or paid
consultants to, the company that owns the technology
evaluated here. As such, however, the penalties could be
severe if this work is someday deemed false or misleading.
Fourth, describing the new method1 for prescribing dialysis
dose to the clinical community, and particularly to clinicians
practicing at FMC(NA)-affiliated clinics, could have altered
traditional practice patterns. The new method was first
published in September 2005; however, all data for this
project were collected before that date. It was not described to
the clinical public by memoranda or verbal presentations,
even to FMC(NA)-affiliated clinics.
Finally, we chose the URR as the familiar dialysis dose
measure. Others may prefer a different measure such as one
of the Kt/V values. There are several such possibilities,
however, and several methods by which each is computed.
The URR is an acknowledged measure of dialysis dose21 and
is the measure routinely reported to the United States
government (Form UB-92 HCFA-1450) as part of its ongoing
management of the dialysis payment program. As such, it is
an appropriate and familiar illustrative example to use for
our purpose.
A debate has occurred in the clinical literature during the
past several years about whether Kt or a urea kinetic
parameter, like the URR or a Kt/V, is the better outcome-
based measure of hemodialysis dose. Those arguments are
well developed elsewhere.10,22 Measures like the URR and Kt/
V are well accepted and have been used in a recent study of
dialysis dose23 and as clinical guidelines for therapy.21 Some
suggest that OLC technology should be used primarily to
measure a K value for use in formal urea kinetic models.2 The
various models have been recently well summarized and
compared.24 The new method1 evaluated here, however,
proposes a more direct use for the new technology that
is predictably associated with death risk. As such, it is a
valid method for judging dialysis dose if OLC measure-
ments are available. It is fortunate that clinicians can now
choose to use either direct Kt measurements or a urea-based
method24 to prescribe and monitor dialysis dose for their
patients.
MATERIALS AND METHODS
All data were taken from the Fresenius Medical Care (North
America) clinical data system. The data management techniques
were similar to those used before.1 Target values for Kt based on the
patients’ BSA were subtracted from the actual Kt delivered during
each dialysis treatment (actual Kttarget Kt) and was the primary
focus for this project. The differences between the URR and a target
URR (target¼ 75%) were also determined for each URR measure-
ment. The medians for all values of BSA, Kt, URR, (actual Kttarget
Kt) and (URRURR target) measured for each patient during
March 2004 were determined and used as predictor measures in
Cox-based analyses of survival time during the 1 year period from
April 1, 2004 through March 31, 2005.
The primary analysis evaluated the association of survival time
with (actual Kttarget Kt). Comparable analyses using a more
familiar treatment measure evaluated (actual URRtarget URR).
Risk profiles were also constructed for Kt, URR, and BSA to evaluate
their comparability with similar analyses reported in the past.3,4,6–8
The variables were grouped according to the decile values of their
distributions. Kt and URR risk profiles were adjusted and not for
BSA and/or certain case mix measure as done in the past. The case
mix measures included age (years), gender (female/male), race
(black/white/other), and diabetic status (diabetic/nondiabetic).
The target Kt (l/treatment) was calculated as a function of BSA
(m2) for each patient using the double reciprocal algebraic form:1
Target Kt ¼ 1
a þ b=BSA ð1Þ
The coefficients ‘a’ and ‘b’ were 0.0069 and 0.0237.1 The URR
was calculated as follows:
URR ¼ 100 1  Post-dialysis BUN
Pre-dialysis BUN
 
ð2Þ
where BUN means blood urea nitrogen concentration.
The primary target value for URR (75%) was chosen because it
was a convenient value close to the median URR and in the range
of minimum risk identified by the URR risk profiles. BSA was
calculated by the DuBois equation.19 Kt was measured using
previously described technology1,2,8 embodied in the model 2008H
and 2008K dialysis hardware systems manufactured and distributed
by the Medical Products Division of Fresenius Medical Care (North
America).
Additional analysis
Possible BSA differences among the deciles of (actual Kttarget Kt)
and (URR75%) were evaluated using an analysis of variance.
Differences among the decile means for each measure were evaluated
using a multiple range test (Scheffe’s test).
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Appendix | Selecting a target Kt by BSA based on Eq. (1).
BSA Kt BSA Kt BSA Kt
1.20 37.6 1.74 48.8 2.28 57.9
1.22 38.0 1.76 49.2 2.30 58.2
1.24 38.5 1.78 49.5 2.32 58.5
1.26 38.9 1.80 49.9 2.34 58.8
1.28 39.4 1.82 50.3 2.36 59.1
1.30 39.8 1.84 50.6 2.38 59.4
1.32 40.3 1.86 51.0 2.40 59.7
1.34 40.7 1.88 51.3 2.42 60.0
1.36 41.2 1.90 51.7 2.44 60.3
1.38 41.6 1.92 52.0 2.46 60.6
1.40 42.0 1.94 52.4 2.48 60.8
1.42 42.4 1.96 52.7 2.50 61.1
1.44 42.9 1.98 53.1 2.52 61.4
1.46 43.3 2.00 53.4 2.54 61.7
1.48 43.7 2.02 53.7 2.56 62.0
1.50 44.1 2.04 54.1 2.58 62.2
1.52 44.5 2.06 54.4 2.60 62.5
1.54 44.9 2.08 54.7 2.62 62.8
1.56 45.3 2.10 55.1 2.64 63.1
1.58 45.7 2.12 55.4 2.66 63.3
1.60 46.1 2.14 55.7 2.68 63.6
1.62 46.5 2.16 56.0 2.70 63.9
1.64 46.9 2.18 56.3 2.72 64.1
1.66 47.3 2.20 56.7 2.74 64.4
1.68 47.7 2.22 57.0 2.76 64.6
1.70 48.0 2.24 57.3 2.78 64.9
1.72 48.4 2.26 57.6 2.80 65.2
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